Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473)

Overview

  • Product nameAnti-VEGF Receptor 2 (phospho Y951) antibodySee all VEGF Receptor 2 primary antibodies ...
  • Description
    Rabbit polyclonal to VEGF Receptor 2 (phospho Y951)
  • SpecificityThis antibody is specific for VEGF Receptor 2 only when phosphorylated at tyrosine 951.
  • Tested applicationsWB, ELISA, IHC-P, ICC/IFmore details
  • Species reactivity
    Reacts with: Mouse, Human
    Predicted to work with: Rat
  • Immunogen

    Synthetic phosphopeptide derived from Human VEGF Receptor 2 around the phosphorylation site of tyrosine 951.

  • Positive control
    • Breast carcinoma tissue and SK-OV3 cell extract.

Properties

Applications

Our Abpromise guarantee covers the use of ab38473 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Detects a band of approximately 190 kDa (predicted molecular weight: 151 kDa).
ELISA 1/20000.
IHC-P Use at an assay dependent dilution.
ICC/IF 1/100.

Target

  • FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CD309 antibody
    • CD309 antigen antibody
    • Fetal liver kinase 1 antibody
    • FLK-1 antibody
    • FLK1 antibody
    • KDR antibody
    • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
    • Kinase insert domain receptor antibody
    • KRD1 antibody
    • Ly73 antibody
    • Protein tyrosine kinase receptor FLK1 antibody
    • Protein-tyrosine kinase receptor flk-1 antibody
    • Tyrosine kinase growth factor receptor antibody
    • Vascular endothelial growth factor receptor 2 antibody
    • VEGFR 2 antibody
    • VEGFR antibody
    • VEGFR-2 antibody
    • VEGFR2 antibody
    • VGFR2_HUMAN antibody
    see all

Anti-VEGF Receptor 2 (phospho Y951) antibody images

  • ab38473 at a 1:50 dilution staining VEGF Receptor 2 in Human breast carcinoma tissue using Immunohistochemistry, Paraffin Embedded Tissue.

    Left image : untreated.

    Right image : treated with phosphopeptide.

  • All lanes : Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473) at 1/500 dilution

    Lane 1 : SK-OV3 cell extract (5-30ug of total protein).
    Lane 2 : SK-OV3 cell extract (5-30ug of total protein). Treated with phosphopeptide.

    Secondary
    Alkaline Phosphatase Goat Anti-Rabbit IgG (H+L)

    Predicted band size : 151 kDa
    Observed band size : 190 kDa (why is the actual band size different from the predicted?)

References for Anti-VEGF Receptor 2 (phospho Y951) antibody (ab38473)

This product has been referenced in:
  • Sangaletti S  et al. Macrophage-derived SPARC bridges tumor cell-extracellular matrix interactions toward metastasis. Cancer Res 68:9050-9 (2008). IHC-P ; Mouse . Read more (PubMed: 18974151) »

See 1 Publication for this product

Product Wall

We are happy to refund your purchase. However it seems that you have purchased this antibody from our distributor in Australia. Could you please contact them and ask them to request a refund from Abcam for you. If the product was in 6 month guarantee p...

Read More

Thank you for confirming these details and for your cooperation. The details provided enable us to closely monitor the quality of our products. I am sorry this product did not perform as stated on the datasheet and for the inconvenience this has ca...

Read More

Thank you for your enquiry regarding ab38473 and for taking the time to provide some useful details of the experiments. I am very sorry to hear that you are having problems with this antibody. The protocol looks fine to me however I would like to a...

Read More
Application Immunocytochemistry/ Immunofluorescence
Sample Mouse Cell (endothelial cells)
Specification endothelial cells
Fixative Paraformaldehyde
Permeabilization Yes - 0.1%Triton/0.1%NP40
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 24°C
Username

Abcam user community

Verified customer

Submitted Oct 18 2008

Application Immunocytochemistry/ Immunofluorescence
Sample Mouse Cell (tumor cell)
Specification tumor cell
Fixative Paraformaldehyde
Permeabilization Yes - 0.1% triton X 100
Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 2% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Sep 19 2007

Thank you for your patience in awaiting a response. As mentioned previously the suggested positive control is rat brain. Briefly the lysate was prepared in the following way: The test was made with whole rat brain tissue. 1) Place the tissue in ...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"